Spero Therapeutics (SPRO) Cash from Investing Activities (2016 - 2022)

Spero Therapeutics (SPRO) has 6 years of Cash from Investing Activities data on file, last reported at -$129000.0 in Q3 2022.

• Quarterly Cash from Investing Activities fell 100.76% year-over-year to -$129000.0 in Q3 2022, while the trailing twelve-month figure through Jun 2023 was -$129000.0 (down 100.47% YoY) and the FY2022 annual result came in at $33.8 million, up 340.65% from the prior year.
• Cash from Investing Activities slipped to -$129000.0 in Q3 2022, from $50.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $50.0 million in Q2 2022 to a low of -$72.6 million in Q3 2018.
• A 5-year average of -$88263.2 and a median of $3.9 million in 2020 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2019 — Cash from Investing Activities soared 396.9% — and 2020, when it plunged 869.5%.
• Tracing SPRO's Cash from Investing Activities over 5 years: stood at $7.3 million in 2018, then sank by 156.25% to -$4.1 million in 2019, then sank by 869.5% to -$39.7 million in 2020, then jumped by 41.43% to -$23.3 million in 2021, then jumped by 99.45% to -$129000.0 in 2022.
• The last three Cash from Investing Activities figures came in at -$129000.0 (Q3 2022), $50.0 million (Q2 2022), and -$16.1 million (Q1 2022), per Business Quant data.